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Abstract
Campylobacter has been associated with immunoproliferative small intestinal disease (IPSID), on the basis of 16S rDNA sequencing, in situ
hybridization, and immunohistochemistry. Here, for the ﬁrst time, we have cultured Campylobacter from the stools of a patient with IPSID.
Phenotypic analysis andwhole genomesequencing identiﬁedCampylobacter coli. PCRona IPSID tissuebiopsy samplewas positive forCampylobacter
coli and negative for Campylobacter jejuni. These ﬁndings further support a causative role for Campylobacter in the development of IPSID.
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Introduction
Immunoproliferative small intestinal disease (IPSID) is a
rare B-cell mucosa-associated lymphoid tissue (MALT) lym-
phoma that involves mainly the proximal small intestine, and is
characterized by the synthesis of a monotypic truncated
immunoglobulin a-heavy chain lacking associated light chains
[1,2]. It is mainly observed in young individuals in developing
countries. On the basis of 16S rDNA sequencing, in situ
hybridization, and immunohistochemistry, IPSID has been
associated with Campylobacter [3,4]. We report here a new
case of IPSID associated with Campylobacter, and the ﬁrst from
which it was cultured. Phenotypic analysis and whole genome
sequencing identiﬁed Campylobacter coli. PCR on an IPSID tissue
biopsy sample was positive for C. coli and negative for Campylo-
bacter jejuni. These ﬁndings further support a causative role for
Campylobacter in IPSID development.
Case Report
A 31-year-old man originating from Guinea and living in France
for 3 years presented on 15 October 2011 with a 5-month
history of severe diarrhoea, abdominal pain, and weight loss of
4 kg, without fever. Two months earlier, he had returned from
a 1-year visit to Guinea, where his symptoms had started.
Physical examination showed a sensitive caecal mass, no
peripheral adenopathy, and no hepatosplenomegaly. Serolog-
ical investigation for human immunodeﬁciency virus-1 gave
negative results, and the blood C-reactive protein level was
133 mg/L. Parasitological examination of stools gave negative
results, and stool cultures were positive for Campylobacter,
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identiﬁed as C. coli on the basis of a negative hippurate assay
result, and conﬁrmed by whole genome sequencing. A
computed tomography scan showed a caeco-ileitis and
numerous coeliac, mesenteric and retroperitoneal supra-cen-
timetre adenopathies.
The patient received azithromycin 500 mg daily without
clinical efﬁcacy, and signs of malabsorption appeared (hypoal-
buminaemia and sideropenic anaemia). A colonoscopy was
performed, and disclosed diffuse small nodules at the mucosal
surface with red petechial spots in the left colon, and a large
and inﬁltrated nodule with enlarged folds and incomplete
stenosis in the ileocaecal junction (Fig. 1a). Histological
examination showed a dense and diffuse lymphoid inﬁltrate
composed of numerous plasma cells and lymphocytes with
centrocyte features, without cytonuclear atypia, which invaded
the glandular epithelium from place to place to form typical
lymphoepithelial lesions (Fig. 1b). No sign of transformation to
high-grade large B-cell lymphoma was observed. Immunohis-
tochemical investigation identiﬁed lymphoid inﬁltrating cells as
strongly positive for CD20, positive for Bcl2, and negative for
Bcl6, CD5, and CD3. The lymphoid inﬁltrate was positive for
a-heavy chain, but negative for j-light chain and k-light chain
(Fig. 1c). Investigation of clonality by PCR of total DNA
extracted from ileocaecal biopsies gave negative results for
B-cells and T-cells. Immunoelectrophoretic analysis of serum
did not demonstrate anti-a-heavy-chain precipitins without
associated light chain. The total serum IgA level was 3.5 g/L.
Oesophagogastroduodenoscopy gave normal ﬁndings.
In order to investigate the presence of C. coli within IPSID
ileocaecal lesions, we performed a PCR speciﬁc for C. jejuni
and C. coli with the CCCJ609F and CCCJ1442R oligonucleo-
tides [5], amplifying the 16S rRNA (rrs) sequence, and a second
PCR amplifying the C. coli aspartate kinase gene, with the
CC519R and CC18F oligonucleotides [5]. Both PCRs were
positive. In contrast, a C. jejuni-speciﬁc PCR amplifying the
hippuricase gene was negative. Together, these results support
the presence of C. coli and the absence of C. jejuni in the IPSID
tissue sample of this patient.
On the basis of the clinical presentation and typical
histopathological features, a diagnosis of ileocaecal IPSID was
made. The absence of anti-a-chain precipitin led to the
diagnosis of non-secreting IPSID. The patient received antimi-
crobial combination therapy with amoxycillin, metronidazole
and clarithromycin for 2 months, and this led to the complete
disappearance of diarrhoea. Stool cultures performed after the
completion of antimicrobial therapy did not isolate Campylo-
bacter.
Three months later, because of asthenia, weight loss, and a
persistent caecal mass, the patient underwent abdominal
positron emission tomography, which showed numerous
hypermetabolism foci at the caecal, mesenteric and splenic
levels (Fig. 1d). A hemi-right colectomy was performed, and
histopathological analysis led to the diagnosis of large B-cell
non-Hodgkin lymphoma (NHL), which was strongly IgA-posi-
tive and negative for light chains. Bone marrow biopsy sampling
did not show NHL extension. While receiving a chemotherapy
course consisting of a ﬁrst round of cyclophosphamide and
three consecutive rounds of rituximab, cyclophosphamide,
doxorubicin, vincristine, and prednisone, the patient presented
with an upper occlusive syndrome and a new lesion of the
fourth duodenum. He received second-line therapy consisting
of four rounds of rituximab, dexamethasone, cytarabine,
cisplatin, and prednisone. He died in the weeks after
completing his second-line treatment in the context of
profound febrile neutropenia and acute renal failure secondary
to obstruction by tumour progression, before he could receive
an allograft from his human leukocyte antigen-compatible
brother.
Discussion
Since the ﬁrst description of a-chain disease in 1968 by
Seligmann et al. in a young Syrian woman [1], approximately
570 cases, also referred as Mediterranean lymphoma or IPSID,
have been published. IPSID mainly occurs in developing
(a) (b) (c) (d)
FIG. 1. (a) Endoscopic aspect of immunoproliferative small intestinal disease (IPSID) tissue at the time of diagnosis. (b) Haematoxylin, eosin and
Safran staining. Intestinal lamina propria inﬁltration by plasma cells and admixed small lymphocytes can be seen. Lymphoepithelial lesions are present.
Original magniﬁcation: 910. (c) Immunohistochemical staining for a-heavy chain. Inﬁltrating lymphoplasmacytes express cytoplasmic a-heavy chain.
Original magniﬁcation: 920. (d) Positron emission tomography image at the time of relapse.
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, 908–911
CMI Coeuret et al. Campylobacter isolated from an IPSID patient 909
countries, historically northern Africa and the Middle East,
with fewer cases from central and southern Africa, eastern
Asia, and sporadic cases in South and Central America. It
mainly affects older children and young adults with low
socio-economic status, with a 2.4 : 1 male/female ratio, and
probably remains frequently undiagnosed [6]. In Tunisia, in a
retrospective study of 153 cases of primary NHL of the gut,
IPSID represented 20% of intestinal NHLs, with an incidence of
0.1/1000 per year [7]. IPSID incidence appears to have sharply
declined in the last decades as a result of improved sanitation
and hygiene, as illustrated recently in a retrospective study
from southern Iran [8].
Clinically, intermittent to chronic diarrhoea and abdominal
pain developing over months are the most frequent symp-
toms, but signs of malabsorption may appear in the course of
the disease, with malnutrition and growth retardation in
children. Abdominal mass, intestinal obstruction, lymphade-
nopathy, hepatomegaly, splenomegaly, bone marrow invasion
or ascites are common in advanced stages. At endoscopic
examination, loss of the mucosal circular folds and a thickened
cobblestone appearance of the mucosa are mostly seen in the
duodenum and upper jejunum, and more rarely in the colon or
stomach. Intestinal tissue biopsies usually show macroscopic
abnormalities [6]. The histopathology of IPSID typically
consists of a proliferation of lymphoplasmocytes and small
centrocyte-like cells that inﬁltrate the mucosa, and ranges
from seemingly benign lymphoid inﬁltration to malignant
diffuse large B-cell lymphoma. As its name indicates, IPSID
lymphoid proliferation is usually restricted to the small
intestine, but it may extend to the stomach and caecum, and
mesenteric lymph nodes. Lymphoid proliferation in the colon
and rectum is rare, and extraintestinal locations involving the
liver, spleen or lung are exceptional. Circulating truncated
a-heavy chain is detected in up to 90% of cases in the serum
by immunoﬁxation electrophoresis, yet non-secreting IPSID is
not considered to be a different entity from secreting IPSID by
the WHO.
Since the initial description of IPSID, antimicrobials have
been used in its early stage, with consistent, albeit usually
temporary, success [1,6]. Incomplete and non-lasting recovery
may indicate high-grade transformation, which requires inten-
sive antineoplastic chemotherapy and bone marrow transplan-
tation [9,10]. There are no internationally validated
therapeutic guidelines for IPSID, and therapeutic decisions
are made on a case-by-case basis.
Given the similar MALT histological features of gastric
lymphoma and ISPID, Isaacson has proposed grouping them
under the term ‘MALT lymphoma’ [2]. Moreover, the fact that
both gastric MALT lymphoma and IPSID respond to antimi-
crobial therapy suggests pathophysiological similarities. It has
now been proven that Helicobacter pylori is the antigenic trigger
that causes gastric MALT lymphoma [11]. In a search for a
putative infectious trigger leading to IPSID development and
accounting for its response to antimicrobial therapy, IPSID
tissue samples were subjected to 16S rDNA sequencing, and
Campylobacter sequences were identiﬁed [3]. Campylobacter
DNA sequences have, to date, been detected in a total of six
of eight IPSID patients [3,4]. In retrospect, it should be noted
that species differentiation between C. jejuni and C. coli could
not be made in these studies, as the oligonucleotide primers
used for 16S rDNA PCR, the probe used for in situ hybrid-
ization and the antibody used for immunohistochemistry are
not able to differentiate these two species.
With the present case, there are now a total of seven of
nine cases studied that have ben associated with Campylobacter,
this one being the ﬁrst in which Campylobacter has been
cultured. In 1992, Puri et al. published a case of IPSID with
diarrhoea caused by C. jejuni in the course of chemotherapy,
presented as a complication of treatment [12].
Several lines of evidence support a causative role for
Campylobacter in IPSID development:
 The demographics of Campylobacter infection or carriage—
transient diarrhoea caused by infection or asymptomatic
chronic carriage of Campylobacter is observed in up to 15%
children in developing countries where IPSID is prevalent, as
compared with <0.5% in developed countries [13].
 A decline in IPSID incidence has been observed in countries
where ISPID was prevalent, such as Tunisia and Iran,
concomitantly with improvements in hygiene and sanitation
[6,7].
 IPSID histopathology and H. pylori-associated MALT lym-
phoma histopathology are similar.
 Antibiotics active against Campylobacter are effective against
IPSID in the early stages, as they are for MALT gastric
lymphoma and H. pylori [3,4].
However, in order to demonstrate a causative role for
Campylobacter in IPSID, Koch’s postulate should ideally be
fulﬁlled. This is now almost the case: (i) there is a very
consistent association between Campylobacter and IPSID,
although in a small series of patients, given the rarity of the
disease; and (ii) Campylobacter has been isolated from the
diseased host. An animal model in which IPSID develops upon
Campylobacter inoculation is now needed to fully demonstrate
Koch’s postulate. We are currently working on the develop-
ment of such a model, and the fact that H. pylori induces MALT
lymphoma in laboratory animals supports the feasibility of this
approach [14,15]. The genome sequence of the C. coli isolate
from this patient shows no obvious particularity, arguing that
Campylobacter behaves in IPSID as does H. pylori in gastric
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MALT lymphoma, as a continuous antigenic trigger favouring
lymphoproliferation [11].
In clinical practice, stool cultures to isolate Campylobacter,
and, in the case of negative results, 16S rDNA PCR on
endoscopic biopsy samples are needed to help prescribe
eradicative anti-Campylobacter antimicrobial therapy. This
constitutes a necessary, albeit probably insufﬁcient, therapeutic
option in IPSID. Further clinical and pathophysiological studies
are needed to better understand IPSID and improve the
prognosis of patients with this disease.
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